OncoMatch

OncoMatch/Clinical Trials/NCT06526793

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Is NCT06526793 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Surovatamig for b-cell non-hodgkin lymphoma.

Phase 2RecruitingAstraZenecaNCT06526793Data as of May 2026

Treatment: Surovatamig — This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Biomarker criteria

Required: CD19 expression (locally confirmed expression in lymphoma cells after progression from last CD19 directed therapy)

Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 2 prior lines

Cannot have received: T-cell engager

Exception: within 8 weeks of first dose

Prior therapy with T-cell engager (TCE) within 8 weeks

Cannot have received: autologous Hematopoietic Stem Cell Transplantation

Exception: within 12 weeks of first dose

autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks

Cannot have received: CAR T-cell therapy

Exception: within 6 months of first dose

CAR T- cell therapy within 6 months

Cannot have received: allogeneic Hematopoietic Stem Cell Transplantation

Exception: within 24 weeks of first dose

prior allogeneic HSCT within 24 weeks of first dose of surovatamig

Lab requirements

Blood counts

ANC ≥ 1000/mm3, platelets ≥ 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening

Kidney function

creatinine clearance (CrCl) of ≥ 45 mL/min

Liver function

total bilirubin <1.5x ULN, AST/ALT ≤ 3xULN or < 5 × ULN in the presence of lymphoma involvement of the liver

Cardiac function

left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA

Adequate hematological function: ANC ≥ 1000/mm3, platelets ≥ 75,000/mm3, hemoglobin ≥ 9 g/dL. Adequate liver function: total bilirubin <1.5x ULN, AST/ALT ≤ 3xULN or < 5 × ULN in the presence of lymphoma involvement of the liver. Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min. Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Phoenix, Arizona
  • Research Site · Duarte, California
  • Research Site · Jacksonville, Florida
  • Research Site · Tampa, Florida
  • Research Site · Chicago, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify